These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18020501)

  • 1. Current Status of CD4-Based Therapies for Prophylaxis and Treatment of HIV Infection.
    Sinclair JP; Shearer WT
    BioDrugs; 1997 Aug; 8(2):128-38. PubMed ID: 18020501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection.
    Schacker T; Collier AC; Coombs R; Unadkat JD; Fox I; Alam J; Wang JP; Eggert E; Corey L
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):145-52. PubMed ID: 7749791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of a radio-iodinatable mutant of recombinant human CD4.
    Ferrer M; Godbout KL; Sullivan BJ; Austen DA; Sanderson CT; Kelley KC; Osburne MS; Harrison SC; van Schravendijk MR
    J Immunol Methods; 1997 Dec; 210(2):215-25. PubMed ID: 9520304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin.
    Ward RH; Capon DJ; Jett CM; Murthy KK; Mordenti J; Lucas C; Frie SW; Prince AM; Green JD; Eichberg JW
    Nature; 1991 Aug; 352(6334):434-6. PubMed ID: 1907354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism.
    Morikita T; Maeda Y; Fujii S; Matsushita S; Obaru K; Takatsuki K
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1291-9. PubMed ID: 9339846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia.
    Schacker T; Coombs RW; Collier AC; Zeh JE; Fox I; Alam J; Nelson K; Eggert E; Corey L
    J Infect Dis; 1994 Jan; 169(1):37-40. PubMed ID: 8277195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janusin: new molecular design for bispecific reagents.
    Traunecker A; Lanzavecchia A; Karjalainen K
    Int J Cancer Suppl; 1992; 7():51-2. PubMed ID: 1428404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial.
    Schooley RT; Merigan TC; Gaut P; Hirsch MS; Holodniy M; Flynn T; Liu S; Byington RE; Henochowicz S; Gubish E
    Ann Intern Med; 1990 Feb; 112(4):247-53. PubMed ID: 2297203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Envelope glycoproteins of HIV-1 interfere with T-cell-dependent B cell differentiation: role of CD4-MHC class II interaction in the effector phase of T cell help.
    Chirmule N; Wang XP; Hu R; Oyaizu N; Roifman C; Pahwa R; Kalyanaraman VS; Pahwa S
    Cell Immunol; 1994 Apr; 155(1):169-82. PubMed ID: 8168144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological properties of a CD4 immunoadhesin.
    Byrn RA; Mordenti J; Lucas C; Smith D; Marsters SA; Johnson JS; Cossum P; Chamow SM; Wurm FM; Gregory T; Groopman JE; Capon DJ
    Nature; 1990 Apr; 344(6267):667-70. PubMed ID: 1970124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus type 1 glycoprotein 120-specific T lymphocytes provide intermolecular help for anti-CD4 autoantibody production in exposed uninfected subjects.
    Furci L; Beretta A; Siccardi A; Lazzarin A; Confetti C; Magnani Z; Scarpellini P; Lopalco L; Burastero SE
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1461-9. PubMed ID: 9390745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
    Van Oijen MG; Preijers FW
    J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
    Shubin Z; Li W; Poonia B; Ferrari G; LaBranche C; Montefiori D; Zhu X; Pauza CD
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28404572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41.
    Allaway GP; Ryder AM; Beaudry GA; Maddon PJ
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):581-7. PubMed ID: 8369162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.
    Traunecker A; Schneider J; Kiefer H; Karjalainen K
    Nature; 1989 May; 339(6219):68-70. PubMed ID: 2541344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV requires multiple gp120 molecules for CD4-mediated infection.
    Layne SP; Merges MJ; Dembo M; Spouge JL; Nara PL
    Nature; 1990 Jul; 346(6281):277-9. PubMed ID: 2374593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AIDS patient monocytes target CD4 T cells for cellular conjugate formation and deletion through the membrane expression of HIV-1 envelope molecules.
    Dudhane A; Wang ZQ; Orlikowsky T; Gupta A; Wormser GP; Horowitz H; Kufer P; Hoffmann MK
    AIDS Res Hum Retroviruses; 1996 Jul; 12(10):893-9. PubMed ID: 8798974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
    Herbeuval JP; Shearer GM
    AIDS Rev; 2006; 8(1):3-8. PubMed ID: 16736946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4.
    Landau NR; Warton M; Littman DR
    Nature; 1988 Jul; 334(6178):159-62. PubMed ID: 3260352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.